Impact of COVID-19 on male urogenital health: Success of vaccines

Kucukyildiz K., YILMAZ ORAL D., Turkcan D., Oztekin C. V., GÜR S.

DRUG DISCOVERY TODAY, cilt.27, sa.10, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 27 Sayı: 10
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.drudis.2022.07.012
  • Dergi Adı: DRUG DISCOVERY TODAY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Biotechnology Research Abstracts, Communication Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Metadex, Civil Engineering Abstracts
  • Anahtar Kelimeler: COVID-19, Urinary bladder, Erectile dysfunction, Prostate, Angiotensin-converting enzyme 2, ANDROGEN DEPRIVATION THERAPY, ERECTILE DYSFUNCTION, CORONAVIRUS, TMPRSS2, FERTILITY, RECEPTOR, SEMEN, ACE2
  • Ankara Üniversitesi Adresli: Evet

Özet

Throughout 2021, the scientific and medical communities were concentrated on dealing with the acute morbidity and mortality induced by the COVID-19 pandemic due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We reviewed the present data for adverse effects of COVID-19 on the different parts of the male urogenital system during the dynamic situation of the COVID-19 pandemic. With the approval of COVID-19 vaccinations, there is a ray of hope at the end of this dark tunnel and a chance to look ahead for the management of long-term consequences in males with urogenital illness. A multidisciplinary investigation of these cases could provide information for establishing and optimizing treatment protocols.